Difference between revisions of "Sapacitabine (CS-682)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "www.ncbi.nlm.nih.gov/pubmed" to "pubmed.ncbi.nlm.nih.gov") Tags: mobile edit mobile web edit |
m |
||
| Line 14: | Line 14: | ||
[[Category:Pyrimidine analogues]] | [[Category:Pyrimidine analogues]] | ||
| − | [[Category:Acute myeloid leukemia medications]] | + | [[Category:Acute myeloid leukemia medications (investigational)]] |
[[Category:Investigational drugs]] | [[Category:Investigational drugs]] | ||
Revision as of 01:58, 26 April 2022
Mechanism of action
Pyrimidine analogue
Preliminary results
Acute myeloid leukemia
- CYC682-06: Kantarjian H, Faderl S, Garcia-Manero G, Luger S, Venugopal P, Maness L, Wetzler M, Coutre S, Stock W, Claxton D, Goldberg SL, Arellano M, Strickland SA, Seiter K, Schiller G, Jabbour E, Chiao J, Plunkett W. Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. Lancet Oncol. 2012 Nov;13(11):1096-104. Epub 2012 Oct 15. link to original article link to PMC article PubMed NCT00590187
Also known as
- Code name: CS-682